ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
2.620
-0.050 (-1.87%)
Dec 20, 2024, 4:00 PM EST - Market closed
ImmunityBio Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for ImmunityBio stock have an average target of 17.38, with a low estimate of 4.75 and a high estimate of 30. The average target predicts an increase of 563.36% from the current stock price of 2.62.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ImmunityBio stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +1,045.04% | Dec 20, 2024 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +1,045.04% | Nov 21, 2024 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +1,045.04% | Nov 19, 2024 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +1,045.04% | Nov 12, 2024 |
| EF Hutton | EF Hutton | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +1,045.04% | Oct 23, 2024 |
Financial Forecast
Revenue This Year
16.63M
from 622.00K
Increased by 2,572.99%
Revenue Next Year
140.92M
from 16.63M
Increased by 747.59%
EPS This Year
-0.69
from -1.15
EPS Next Year
-0.51
from -0.69
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 17.1M | 179.3M | 284.0M | |||
| Avg | 16.6M | 140.9M | 275.9M | |||
| Low | 16.0M | 111.3M | 265.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 2,651.6% | 978.4% | 101.5% | |||
| Avg | 2,573.0% | 747.6% | 95.8% | |||
| Low | 2,468.2% | 569.6% | 88.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.70 | -0.44 | -0.28 | |||
| Avg | -0.69 | -0.51 | -0.28 | |||
| Low | -0.67 | -0.57 | -0.26 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.